Judah Frommer, an analyst from Morgan Stanley, maintained the Buy rating on Kymera Therapeutics. The associated price target remains the same with $70.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Judah Frommer has given his Buy rating due to a combination of factors related to Kymera Therapeutics’ promising developments in their research and clinical trials. The company announced that its Phase 1 human volunteer data was selected for a late-breaking presentation at the European Academy of Dermatology and Venereology (EADV) 2025, indicating the significance and potential impact of their findings.
Additionally, Kymera presented new preclinical data showing that their treatment demonstrated activity similar to dupilumab in IL-4 stimulated keratinocytes, which is encouraging for addressing Th2-driven conditions such as atopic dermatitis. This data supports the potential effectiveness of their STAT6 degradation approach, further bolstering confidence in their upcoming Phase 1b readout scheduled for the fourth quarter of 2025.
In another report released on September 16, RBC Capital also initiated coverage with a Buy rating on the stock with a $70.00 price target.
KYMR’s price has also changed moderately for the past six months – from $34.490 to $48.120, which is a 39.52% increase.